Quibim partners with Merck to develop next wave of imaging-based diagnostics for precision medicine

Quibim, the global company transforming imaging data into actionable predictions of cancer progression and treatment response, is collaborating with science and technology company Merck KGaA to develop the next generation of precision medicine technology targeting a wide range of cancers. 

The two companies are exploring how to harness the potential of biomarkers and radiomics to predict a cancer patient’s response to immunotherapy and anticipate cancer patient outcomes.

Quibim will contribute its years of expertise in utilizing AI to develop predictive and prognostic models able to enhance patient stratification and contextualize potential benefits of novel therapies at a patient-, dose- and/or treatment level.

Merck KGaA seeks to integrate these models as it continues to advance data-driven decision-making within its global drug development and commercialization strategies.

Enhancing the efficiency of clinical development for cancer medicine is a critical and global challenge, particularly in light of the rapidly increasing number of cancer patients in need of personalized treatment.

According to the Global Cancer Observatory, there will be an estimated 30 million new cases of cancer worldwide each year by 2040, up from 19 million in 2020. To face this, Quibim and Merck KGaA, Darmstadt, Germany’s research will be laser-focused on finding technological solutions able to reduce costs and timelines for pharmaceutical development while also improving success rates.

Angel Alberich-Bayarri, Co-Founder and CEO of Quibim, said: “Our partnership with Merck KGaA, Darmstadt, Germany is poised to be a game-changer in the field of oncology by applying our cutting-edge imaging-based methodologies.

“We’re on a mission to optimize each phase of clinical development and chart a course towards a new era in precision medicine, where data-driven insights enhance patient care and deliver more efficient, effective and tailored treatments.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news